u 69593 has been researched along with 4-[[(4-methylphenyl)sulfonylamino]methyl]-N-[2-[(phenylmethyl)-propan-2-ylamino]ethyl]benzamide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aubé, J; Bohn, LM; Frankowski, KJ; Lovell, KM; Phillips, AM; Prisinzano, TE; Schoenen, FJ; Slauson, SR; Streicher, JM; Whipple, DA; Zhou, L | 1 |
1 other study(ies) available for u 69593 and 4-[[(4-methylphenyl)sulfonylamino]methyl]-N-[2-[(phenylmethyl)-propan-2-ylamino]ethyl]benzamide
Article | Year |
---|---|
Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.
Topics: Animals; Arrestins; Benzamides; beta-Arrestins; Chemistry Techniques, Synthetic; CHO Cells; Cricetulus; Drug Evaluation, Preclinical; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Structure-Activity Relationship; Sulfonamides; Tetrahydroisoquinolines | 2015 |